Notable analyst calls this week: Broadcom, Moderna and Abbott among top picks
Analysts made notable calls this week. D.A. Davidson upgraded Broadcom (AVGO) to Buy with a $400 price target, citing AI-related growth prospects. William Blair downgraded Moderna (MRNA) to Market Perform due to valuation concerns. Argus downgraded Abbott (ABT) to Hold after its reduced growth outlook. Jefferies upgraded Rivian (RIVN) to Buy, citing progress in margins and execution. GF Securities raised AMD's (AMD) price target to $720, expecting strong data center growth.
How this was made
The 30-second read
Why it matters
The upgrades and downgrades provide fresh directional cues for traders, especially ahead of upcoming earnings for AMD and broader AI hype.
Market read
Analyst rating actions create short‑term trading opportunities across the highlighted tickers.
What to watch
Potential supply‑chain constraints and macro‑economic headwinds could temper upside.
Background
Weekly analyst rating changes across technology, biotech, and medical device sectors.
Ticker impact
D.A. Davidson upgraded Broadcom to Buy and raised the price target to $400.
likely upward pressure as analysts see upside from AI partnership expectations
Upgrade and higher target suggest market may bid the stock higher.
William Blair downgraded Moderna to Market Perform citing valuation after a late‑stage cancer shot win.
potential downside as valuation concerns surface
Downgrade and lower expectations can trigger sell pressure.
Argus Research cut Abbott to Hold from Buy after the company trimmed its full‑year sales growth outlook.
likely pressure as slower growth outlook is priced in
Guidance reduction often leads to short‑term price weakness.
Jefferies upgraded Rivian to Buy from Hold, citing a price‑correction entry point and progress toward positive margins.
upward bias as analysts highlight margin improvement
Buy upgrade and target raise tend to attract buying interest.
GF Securities raised AMD's price target to $720 ahead of its Q3 results.
potential upside ahead of earnings release
Higher target signals confidence in upcoming results, supporting price gains.
Market effects
AI‑related upgrades may lift broader semiconductor and biotech sentiment.
U.S. equities could see modest sector rotation toward upgraded names.
Limited to U.S. listed companies; no direct global macro impact.
Counterpoint
Some investors may view the upgrades as premature given broader market volatility.
Key entities
- analyst_firmD.A. Davidson
Upgraded Broadcom to Buy
- analyst_firmWilliam Blair
Downgraded Moderna
- analyst_firmArgus Research
Cut Abbott to Hold
- analyst_firmJefferies
Upgraded Rivian to Buy
- analyst_firmGF Securities
Raised AMD price target
